Long-acting GLP-1 receptor agonist. GLP1R variants (rs6923761) modulate weight-loss response.
Modified GLP-1(7-37) with fatty-acid acylation for albumin binding (≈1 week half-life). STEP trials show 15-17% body weight reduction at 68 weeks. SELECT trial extends evidence to cardiovascular outcomes in non-diabetics.
Compounded semaglutide (gray market) is no longer permitted by FDA after the shortage ended (2024). Verify your source's legal posture. Same GI titration requirement as tirzepatide.
Aib at position 2; C18 fatty acid conjugated at K20 via γGlu-2×OEG linker.
Known risk or pharmacological conflict.
Stack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
STEP showed 14.9% weight loss at 68 weeks in obesity. SELECT showed 20% reduction in major adverse cardiovascular events in patients with overweight/obesity + established CVD — the first weight-loss drug with proven CV outcome data.
Source →Useful tool for the metabolic-syndrome end of obesity but argues GLP-1s shouldn't substitute for fixing the food environment. Concerned about long-term dependence and post-discontinuation rebound. Critical of telehealth chains that prescribed without metabolic workup.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 0.25-2.4 mg · weekly, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Dosing assumption: 1.0-1.7 mg weekly (steady-state weight-management dose)
Wegovy (obesity) and Ozempic (T2D). NovoCare direct-pay program at lower bound. Insurance coverage variable.
As of 2026-04Not currently legal in US — FDA declared shortage resolved May 2025.
As of 2026-04Ozempic + Wegovy widely available in COFEPRIS-registered MX pharmacies. Border pharmacies higher counterfeit rate.
As of 2026-04Research-grey range. Same caveats as Tirzepatide grey market.
As of 2026-04Public-source attribution across the production + distribution chain. Stack does not endorse vendors — this is who is in the chain, not which one is best.
Swiss-headquartered global peptide API manufacturer with FDA-registered facilities. Supplies APIs to multiple FDA-approved drug brands.
China-based peptide API maker with semaglutide and tirzepatide listed on US FDA Green List. Also certified by China NMPA, EU EDQM, South Korea MFDS.
FDA-inspected peptide API manufacturer with US and China facilities. 500+ chemists.
FDA approved (Ozempic / Wegovy)
FDA declared the Semaglutide shortage resolved in May 2025. Compounded Semaglutide (sold as 'Wegovy alternatives' by telehealth chains) is no longer permitted in the US. The shutdown applied to both 503A and 503B pharmacies.
COFEPRIS issued formal warnings about counterfeit Ozempic, Wegovy, and Saxenda circulating in Mexican gray markets, particularly in border-state pharmacies catering to US cross-border traffic. Several seizures documented in Tijuana, Juárez, and Reynosa.
FDA approved an expanded label for Semaglutide (Wegovy) to reduce risk of cardiovascular death, heart attack, and stroke in adults with overweight/obesity + established cardiovascular disease. Based on the SELECT trial.
COFEPRIS (Mexican federal health regulator) continued to require physician prescription for GLP-1 agonists through 2023-2024 despite high obesity prevalence and pharmacy-tourism demand from US patients. Compounding less restrictive than US 503A regime.
ANMAT (Argentina), INVIMA (Colombia), and ANVISA (Brazil) all regulate GLP-1 agonists as prescription drugs. Brazil is the strictest enforcement jurisdiction in LATAM. Argentina has a more porous regime in practice. Colombia sits in the middle. Cross-border GLP-1 supply between LATAM countries is real but not as developed as US-Mexico flow.